Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters
<b>Background/Objectives:</b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has rapidly evolved, giving rise to multiple Variants of Concern—including Alpha, Beta, Gamma, Delta, and Omicron—which emerged independ...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/6/633 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839652461465305088 |
|---|---|
| author | Qingmei Jia Helle Bielefeldt-Ohmann Saša Masleša-Galić Richard A. Bowen Marcus A. Horwitz |
| author_facet | Qingmei Jia Helle Bielefeldt-Ohmann Saša Masleša-Galić Richard A. Bowen Marcus A. Horwitz |
| author_sort | Qingmei Jia |
| collection | DOAJ |
| description | <b>Background/Objectives:</b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has rapidly evolved, giving rise to multiple Variants of Concern—including Alpha, Beta, Gamma, Delta, and Omicron—which emerged independently across different regions. Licensed COVID-19 vaccines primarily target the highly mutable spike protein, resulting in reduced efficacy due to immune escape by emerging variants. Previously, we developed a live attenuated <i>Francisella tularensis</i> LVS Δ<i>capB</i> single-vector platform COVID-19 vaccine, rLVS Δ<i>capB</i>/MN, expressing the conserved membrane (M) and nucleocapsid (N) proteins from the early SARS-CoV-2 WA-01/2020 strain. In this study, we evaluate the efficacy of rLVS Δ<i>capB</i>/MN and an enhanced version, rLVS Δ<i>capB</i>::RdRp/MN, which additionally expresses the conserved RNA-dependent RNA polymerase (RdRp) protein from the same strain, in a hamster model. <b>Methods:</b> Both vaccine candidates were administered orally or intranasally to golden Syrian hamsters (equal numbers of males and females) and evaluated against intranasal challenge with SARS-CoV-2 Delta (B.1.617.2-AY.1) and Omicron (BA.5) variants. <b>Results:</b> Vaccinated animals developed robust, TH1-biased IgG responses specific to the nucleocapsid protein. Following SARS-CoV-2 challenge, immunized hamsters exhibited reduced weight loss, lower oropharyngeal and lung viral titers, and improved lung pathology scores compared with unvaccinated controls. <b>Conclusion:</b> These findings support the potential of this universal vaccine to provide broad protection against current and future SARS-CoV-2 variants, with minimal need for updating. |
| format | Article |
| id | doaj-art-80ad65dbff5a47b09e19de3885c0d6e1 |
| institution | Matheson Library |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-80ad65dbff5a47b09e19de3885c0d6e12025-06-25T14:30:07ZengMDPI AGVaccines2076-393X2025-06-0113663310.3390/vaccines13060633Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in HamstersQingmei Jia0Helle Bielefeldt-Ohmann1Saša Masleša-Galić2Richard A. Bowen3Marcus A. Horwitz4Division of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California—Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USAAustralian Infectious Diseases Research Centre, University of Queensland, St Lucia, QLD 4072, AustraliaDivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California—Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USADepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USADivision of Infectious Diseases, Department of Medicine, 32-150 Center for Health Sciences, School of Medicine, University of California—Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA<b>Background/Objectives:</b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has rapidly evolved, giving rise to multiple Variants of Concern—including Alpha, Beta, Gamma, Delta, and Omicron—which emerged independently across different regions. Licensed COVID-19 vaccines primarily target the highly mutable spike protein, resulting in reduced efficacy due to immune escape by emerging variants. Previously, we developed a live attenuated <i>Francisella tularensis</i> LVS Δ<i>capB</i> single-vector platform COVID-19 vaccine, rLVS Δ<i>capB</i>/MN, expressing the conserved membrane (M) and nucleocapsid (N) proteins from the early SARS-CoV-2 WA-01/2020 strain. In this study, we evaluate the efficacy of rLVS Δ<i>capB</i>/MN and an enhanced version, rLVS Δ<i>capB</i>::RdRp/MN, which additionally expresses the conserved RNA-dependent RNA polymerase (RdRp) protein from the same strain, in a hamster model. <b>Methods:</b> Both vaccine candidates were administered orally or intranasally to golden Syrian hamsters (equal numbers of males and females) and evaluated against intranasal challenge with SARS-CoV-2 Delta (B.1.617.2-AY.1) and Omicron (BA.5) variants. <b>Results:</b> Vaccinated animals developed robust, TH1-biased IgG responses specific to the nucleocapsid protein. Following SARS-CoV-2 challenge, immunized hamsters exhibited reduced weight loss, lower oropharyngeal and lung viral titers, and improved lung pathology scores compared with unvaccinated controls. <b>Conclusion:</b> These findings support the potential of this universal vaccine to provide broad protection against current and future SARS-CoV-2 variants, with minimal need for updating.https://www.mdpi.com/2076-393X/13/6/633vaccinesingle-vector platformLVS Δ<i>capB</i> vectorCOVID-19SARS-CoV-2membrane protein |
| spellingShingle | Qingmei Jia Helle Bielefeldt-Ohmann Saša Masleša-Galić Richard A. Bowen Marcus A. Horwitz Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters Vaccines vaccine single-vector platform LVS Δ<i>capB</i> vector COVID-19 SARS-CoV-2 membrane protein |
| title | Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters |
| title_full | Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters |
| title_fullStr | Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters |
| title_full_unstemmed | Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters |
| title_short | Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters |
| title_sort | universal bacterium vectored covid 19 vaccine expressing early sars cov 2 conserved proteins cross protects against late variants in hamsters |
| topic | vaccine single-vector platform LVS Δ<i>capB</i> vector COVID-19 SARS-CoV-2 membrane protein |
| url | https://www.mdpi.com/2076-393X/13/6/633 |
| work_keys_str_mv | AT qingmeijia universalbacteriumvectoredcovid19vaccineexpressingearlysarscov2conservedproteinscrossprotectsagainstlatevariantsinhamsters AT hellebielefeldtohmann universalbacteriumvectoredcovid19vaccineexpressingearlysarscov2conservedproteinscrossprotectsagainstlatevariantsinhamsters AT sasamaslesagalic universalbacteriumvectoredcovid19vaccineexpressingearlysarscov2conservedproteinscrossprotectsagainstlatevariantsinhamsters AT richardabowen universalbacteriumvectoredcovid19vaccineexpressingearlysarscov2conservedproteinscrossprotectsagainstlatevariantsinhamsters AT marcusahorwitz universalbacteriumvectoredcovid19vaccineexpressingearlysarscov2conservedproteinscrossprotectsagainstlatevariantsinhamsters |